Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients.

Although the comparisons of RPR-positive rate among anti-HDV-positive and anti-HDV-negative participants in our study did not reach statistical significance (57.5% versus 41.6%), our findings suggested a tendency for HDV to be sexually transmitted among PLWH.

also in 111,027 other papers